iCAD to Present at Rodman & Renshaw 12th Annual Global Investment Conference

Webcast Scheduled for September 15, 2010 at 10:25 a.m. Eastern Time

NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will be presenting a corporate update at the Rodman & Renshaw 12^th Annual Global Investment Conference on September 15, 2010 at 10:25 a.m. (Eastern time) being held at the New York Palace Hotel in New York City.

Management will also be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Growth Conference on September 14-15, 2010. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [e-mail] or contact your Rodman & Renshaw representative.

The presentation will be webcast live and archived for replay on the “Investors” section of the company’s website at www.icadmed.com and at http://www.wsw.com/webcast/rrshq18/icad.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, more than 3,800 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate, and colon, and, in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.